DUBLIN – Vectura Group plc is acquiring Skyepharma plc in a deal that values the latter firm at £441.3 million (US$622 million) or 410.15 pence per share. The transaction will create a U.K.-based respiratory drug delivery specialist with pro forma annual revenues of £153.9 million and with a position in each of the industry's three key technology areas: dry powder inhalers, pressurized metered dose inhalers and nebulizers.